Table 3.
Risk of Colorectal Cancer in 208 Pediatric Patients with Ulcerative Colitis Analyzed by the Log-Rank Test
| Variable | No. of patients | Colorectal cancer |
p-value |
|---|---|---|---|
| Age group | NC | ||
| A1a (0–9 yr) | 5 | 0 | |
| A1b (10–16 yr) | 158 | 3 | |
| A2 (17 yr) | 45 | 0 | |
| Sex | 0.759 | ||
| Male | 119 | 2 | |
| Female | 89 | 1 | |
| Family history of IBD | 0.410 | ||
| No | 185 | 3 | |
| Yes | 23 | 0 | |
| Extent at diagnosis | NC | ||
| Ulcerative proctitis (E1) | 55 | 0 | |
| Left-sided colitis (E2) | 53 | 0 | |
| Extensive colitis (E3) | 10 | 0 | |
| Pancolitis (E4) | 73 | 3 | |
| Maximum extent during follow-up | 0.302 | ||
| Ulcerative proctitis (E1) | 32 | 0 | |
| Left-sided colitis (E2) | 41 | 0 | |
| Extensive colitis (E3) | 15 | 0 | |
| Pancolitis (E4) | 103 | 3 | |
| ANCA | 0.642 | ||
| Negative | 92 | 2 | |
| Positive | 101 | 1 | |
| PSC | 0.002 | ||
| Negative | 196 | 1 | |
| Positive | 12 | 2 | |
| EIM | 0.113 | ||
| Negative | 174 | 2 | |
| Positive | 31 | 1 | |
| PUCAI at diagnosis | NC | ||
| Remission | 5 | 0 | |
| Mild | 75 | 1 | |
| Moderate | 87 | 8 | |
| Severe | 28 | 8 | |
| AOI | 0.579 | ||
| Negative | 172 | 3 | |
| Positive | 36 | 0 | |
| Systemic corticosteroid | 0.359 | ||
| Negative | 64 | 0 | |
| Positive | 144 | 3 | |
| Immunosuppressant | 0.594 | ||
| Negative | 132 | 2 | |
| Positive | 72 | 1 | |
| Anti-TNF-α | NC | ||
| Negative | 188 | 3 | |
| Positive | 20 | 0 |
IBD, inflammatory bowel disease; ANCA, antineutrophil cytoplasmic antibody; PSC, primary sclerosing cholangitis; EIM, extraintestinal manifestation; PUCAI, Pediatric Ulcerative Colitis Activity Index; AOI, appendiceal orifice inflammation; TNF, tumor necrosis factor; NC, not calculable.